Elektra Health Medical Leadership and Credentials: An Independent Review

What Is Elektra Health and How Does It Work?

Elektra Health operates as a direct-to-consumer telehealth service built around a single clinical niche: menopause. Founded in 2019, the platform pairs patients with clinicians for video-based consultations and, where clinically appropriate, prescribes hormone therapy including estrogen, progesterone, and low-dose testosterone. It also offers structured health coaching as a non-prescribing tier.

The company positions itself as a resource for the estimated 1.3 million U.S. Women who enter menopause each year, a figure cited by the CDC's reproductive health data program. Whether the platform delivers on that positioning depends heavily on the qualifications of its clinical staff and how consistently care aligns with evidence-based guidelines.

The Insurance-Plus-Cash Model Explained

Elektra accepts a limited but growing list of insurance plans, including certain Blue Cross Blue Shield and Aetna products, though coverage varies by state and plan type. Patients without covered benefits can pay out of pocket. Initial consultations have ranged from roughly $200 to $295 depending on provider type and plan configuration. Follow-up visits tend to run lower, typically in the $75 to $150 range.

This hybrid model matters clinically. Patients on insurance plans face fewer financial barriers to follow-up, which is relevant because the Menopause Society's 2022 hormone therapy position statement explicitly notes that individualized, ongoing monitoring is expected when systemic HRT is prescribed. Platforms that make follow-up cost-prohibitive may inadvertently undermine safe prescribing.

Health Coaching as a Parallel Track

Alongside prescribing clinicians, Elektra employs health coaches who hold board certifications through organizations such as the National Board for Health and Wellness Coaching (NBHWC). Coaches do not prescribe. They focus on lifestyle modification, sleep hygiene, nutrition, and stress management, which are all evidence-supported adjuncts to pharmacologic menopause management. The North American Menopause Society notes that non-hormonal options and lifestyle interventions remain first-line or adjunct approaches for specific symptom clusters, including mild vasomotor symptoms.

Medical Leadership: Who Leads the Clinical Team?

Elektra Health lists physician leaders on its public website, though the depth of credential disclosure varies. At the time of this review, the company's chief medical officer role has been held by physicians with listed training in obstetrics and gynecology or internal medicine with a menopause subspecialty focus.

Verifying Physician Credentials

State medical boards are the ground truth for physician licensure. Every U.S. Physician must hold an active, unrestricted license in the state where the patient is located at the time of the telehealth visit. Consumers can verify any Elektra clinician's license in under two minutes using their state's medical board lookup tool. A starting directory is maintained by the Federation of State Medical Boards. No disciplinary actions against named Elektra physicians were identified in a search conducted for this review, though consumers should run their own real-time lookups because board records update continuously.

NAMS Certification and Menopause-Specific Training

The Menopause Society (formerly NAMS) administers the Menopause Practitioner (NCMP) certification exam, which is the most widely recognized credential for menopause specialization in the United States. Passing requires demonstrated knowledge of the full NAMS curriculum, including hormonal and non-hormonal therapy, genitourinary syndrome of menopause, cardiovascular risk stratification, and bone health.

Elektra's marketing material references alignment with NAMS guidelines. Patients can ask directly during an intake call whether their assigned clinician holds NCMP certification or has completed equivalent fellowship training. This single question is among the most useful credential checks a patient can perform.

Nurse Practitioners and Advanced Practice Providers

Elektra also staffs nurse practitioners (NPs) and other advanced practice providers (APPs). NPs in menopause care can prescribe hormone therapy in most states under full-practice authority, which at least 26 states and Washington D.C. Currently grant. In restricted-practice states, NP prescribing requires a supervising physician agreement. Patients in those states should ask Elektra directly whether its NPs operate under a valid supervision agreement in their state, since that agreement is a legal prerequisite for valid prescriptions.

Is Elektra Health Legitimate? Regulatory and Accreditation Review

Legitimacy in telehealth has a specific technical meaning. A platform is operating legitimately when its prescribers hold active state licenses, prescriptions are issued only after a valid patient-prescriber relationship is established, pharmacies used are licensed and verified, and no active FDA or DEA enforcement actions exist against the entity.

FDA Enforcement Record

A search of the FDA's warning letter database returned no results for Elektra Health as of the publication date of this article. FDA warning letters related to telehealth typically address unlicensed drug dispensing, unapproved compounded product promotion, or off-label claims that cross into misbranding territory. The absence of a warning letter is a meaningful but not conclusive indicator of compliance.

LegitScript Verification

LegitScript is an independent certification body that evaluates online pharmacies and telehealth platforms for compliance with U.S. Law. Their healthcare merchant certification database is searchable. At time of writing, a specific LegitScript certification for Elektra Health was not identified, but the absence of a LegitScript warning or "rogue" designation is also notable. Patients who want maximum assurance can request that Elektra disclose which pharmacy partners it uses and then verify those pharmacies independently via the NABP's VIPPS database.

Better Business Bureau Profile

Elektra Health does not carry BBB accreditation as of mid-2025. The BBB profile shows a limited complaint history relative to platform size, with complaints in the customer-service and billing categories rather than patient safety categories. BBB ratings are not a clinical quality metric, but a pattern of billing disputes can reflect administrative dysfunction that affects care continuity.

State Telehealth Prescribing Compliance

The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person or video-based medical evaluation before a provider prescribes controlled substances via telehealth. Estrogen and most progesterone formulations are not controlled substances, so this rule does not apply to the core Elektra formulary. Low-dose testosterone, which Elektra may prescribe off-label for libido, is a Schedule III controlled substance, and the Ryan Haight requirements do apply. Patients receiving testosterone prescriptions from Elektra should confirm they received a synchronous video visit, not just a questionnaire-based intake.

How Elektra's Clinical Protocols Compare to NAMS and ACOG Guidelines

Evidence-based menopause care in 2025 is anchored by two primary guideline documents: the 2022 Menopause Society Hormone Therapy Position Statement and the American College of Obstetricians and Gynecologists (ACOG) Menopause Practice Bulletin. Any reputable menopause platform should be prescribing and counseling in alignment with both.

Vasomotor Symptom Management

The 2022 NAMS position statement concludes that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." Elektra's clinical messaging largely reflects this timing hypothesis, which is clinically appropriate given the trial data.

The REPLENISH trial (N=1,835) demonstrated that the combination 17-beta estradiol/progesterone oral capsule (brand name Bijuva) significantly reduced mean moderate-to-severe hot flash frequency versus placebo at 12 weeks, with a safety profile consistent with prior systemic HRT data (PMID 30561480). Elektra's formulary includes FDA-approved bioidentical estradiol formulations, which aligns with the NAMS preference for regulated products over unregulated compounded BHRT when FDA-approved options exist.

Genitourinary Syndrome of Menopause (GSM)

GSM, characterized by vaginal dryness, dyspareunia, and urinary symptoms, affects an estimated 27 to 84% of postmenopausal women depending on diagnostic criteria used, per a systematic review in Menopause journal (PMID 26125688). Low-dose vaginal estrogen is first-line therapy for isolated GSM per both NAMS and ACOG, and it does not carry the systemic risk profile of oral estrogen.

Elektra lists vaginal estrogen products among its prescribing options. This is appropriate. A platform that defaulted to systemic HRT for isolated GSM when a patient has no systemic vasomotor symptoms would represent a protocol gap worth raising with the prescriber.

Non-Hormonal Pharmacologic Options

Not every patient is a candidate for hormone therapy. Contraindications include active or recent hormone-sensitive cancers, unexplained vaginal bleeding, active thromboembolic disease, and certain cardiovascular conditions. For these patients, the FDA-approved non-hormonal option fezolinetant (Veozah), a neurokinin 3 receptor antagonist, received approval in May 2023 specifically for moderate-to-severe vasomotor symptoms. The SKYLIGHT 1 trial (N=475) showed fezolinetant 45 mg reduced mean hot flash frequency by 60.5% from baseline at 12 weeks versus 44.1% for placebo (PMID 36469820). Patients who are not hormone therapy candidates should ask Elektra clinicians directly whether fezolinetant is available in their state formulary.

Patient Complaints: Patterns and What They Mean Clinically

Online complaint data for Elektra Health, drawn from sources including the BBB, Trustpilot, and the Apple App Store, shows a pattern common to many telehealth platforms. Most negative reviews cluster around four themes: insurance billing errors, delayed prescription routing, difficulty reaching a live clinician, and frustration when a specific hormone formulation was not offered.

Billing and Insurance Disputes

Billing complaints are not a patient safety issue by themselves, but they can become one if patients abandon care because of financial confusion. The National Women's Health Network has consistently noted that administrative friction in reproductive and menopausal health care disproportionately affects women who are already managing complex symptoms. Patients should request an itemized cost estimate before their first Elektra visit and confirm their plan's telehealth menopause coverage in writing.

Prescription Routing Delays

Several reviewers report a gap between the end of their consultation and pharmacy receipt of a prescription, ranging from 24 hours to several days. This does not indicate illegal conduct, but it suggests that Elektra's electronic prescribing workflow may not be fully automated. Patients on time-sensitive regimens, such as those restarting systemic HRT after a treatment gap, should flag timing expectations at the close of their visit.

Clinician Availability and Continuity

A recurring complaint involves patients being assigned a different clinician at each visit rather than maintaining a consistent provider relationship. Continuity of care in menopause management matters because dose titration decisions, symptom tracking, and safety monitoring (such as annual breast and cardiovascular risk reassessment recommended by NAMS) depend on a longitudinal record interpreted by a consistent clinician. Patients should ask Elektra whether care continuity can be requested or guaranteed before signing up.

The HealthRX Menopause Telehealth Credential Checklist

The following five-point framework was developed by the HealthRX medical team to help patients evaluate any menopause telehealth platform, including Elektra Health:

1. License verification. Confirm your assigned clinician holds an active, unrestricted license in your state using FSMB or your state board lookup. Takes under three minutes.
2. NCMP or equivalent credential. Ask directly whether your clinician holds the Menopause Society's NCMP certification or has completed an ob-gyn residency with menopause fellowship training.
3. FDA-approved formulary. Confirm the platform prescribes FDA-approved estradiol, progesterone, and, where appropriate, fezolinetant rather than defaulting to unregulated compounded products without a documented clinical rationale.
4. Supervision agreement disclosure (if NP-staffed). In restricted-practice states, request written confirmation that supervising physician agreements are current and on file.
5. Continuity mechanism. Ask how the platform handles annual HRT safety reviews and whether you can be assigned a consistent provider.

Any reputable menopause telehealth platform should answer all five questions clearly and in writing.

Compounded Bioidentical Hormones: Where Elektra Stands

The NAMS 2022 position statement states directly: "Compounded bioidentical hormones are not recommended because of concerns about efficacy, safety, and inconsistent formulations." The FDA has issued multiple guidance documents noting that compounded hormones do not carry the same safety and efficacy data as FDA-approved products.

Elektra's public-facing clinical content aligns with this guidance. The platform does not appear to market custom-compounded BHRT pellets or troches as primary offerings, which differentiates it from several competing platforms that have received FDA scrutiny. Patients who are offered compounded products by any telehealth provider should ask for the clinical rationale explaining why an FDA-approved alternative was not selected first.

Cost Transparency and Value Assessment

A meaningful menopause care program involves more than a single prescription. ACOG guidance and NAMS both recommend baseline lipid panels, blood pressure assessment, fracture risk screening with FRAX scoring, and mammography coordination as part of comprehensive menopause management. Telehealth platforms cannot perform physical exams, so the question becomes whether Elektra's clinicians actively order or coordinate these tests.

The out-of-pocket cost for an initial Elektra visit (approximately $200 to $295) is competitive with the self-pay rates at many in-person gynecology offices for a comparable consultation. The value equation shifts, though, if the platform does not coordinate lab work or fails to flag when an in-person referral is warranted (for example, for unexplained postmenopausal bleeding, which requires endometrial biopsy or transvaginal ultrasound that telehealth cannot provide).

Patients paying cash should ask at intake whether lab requisitions are included in the visit fee or billed separately.

Summary Assessment: Strengths and Gaps

Strengths identified:

• Menopause-exclusive clinical focus rather than a generalist telehealth model
• References to NAMS guideline alignment in clinical content
• Hybrid insurance/cash model reduces financial barriers versus cash-only competitors
• No active FDA enforcement actions or LegitScript warning flags identified
• Health coaching tier provides a non-prescribing entry point for lifestyle management

Gaps to watch:

• Credential depth of individual clinicians is not consistently disclosed at the individual provider level
• Care continuity structure is unclear from public-facing materials
• Prescription routing timelines could be clarified before sign-up
• It is not confirmed whether fezolinetant (Veozah) is available across all states served
• NCMP certification rate among clinical staff is not publicly reported

The gaps listed above are common across the telehealth sector, not unique to Elektra. Patients can close most of these gaps by asking the five questions in the HealthRX checklist above before committing to a plan.